Logo image of 4AB.DE

ABBVIE INC (4AB.DE) Stock Fundamental Analysis

Europe - Frankfurt Stock Exchange - FRA:4AB - US00287Y1091 - Common Stock

187.2 EUR
-0.2 (-0.11%)
Last: 1/16/2026, 5:28:00 PM
Fundamental Rating

5

4AB gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 83 industry peers in the Biotechnology industry. While 4AB is still in line with the averages on profitability rating, there are concerns on its financial health. 4AB has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • 4AB had positive earnings in the past year.
  • In the past year 4AB had a positive cash flow from operations.
  • 4AB had positive earnings in each of the past 5 years.
  • In the past 5 years 4AB always reported a positive cash flow from operatings.
4AB.DE Yearly Net Income VS EBIT VS OCF VS FCF4AB.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 1.75%, 4AB is in the better half of the industry, outperforming 75.90% of the companies in the same industry.
  • 4AB has a better Return On Invested Capital (15.64%) than 91.57% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for 4AB is in line with the industry average of 12.74%.
  • The 3 year average ROIC (13.67%) for 4AB is below the current ROIC(15.64%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 1.75%
ROE N/A
ROIC 15.64%
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
4AB.DE Yearly ROA, ROE, ROIC4AB.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100

1.3 Margins

  • 4AB has a Profit Margin of 3.94%. This is in the better half of the industry: 4AB outperforms 79.52% of its industry peers.
  • 4AB's Profit Margin has declined in the last couple of years.
  • With an excellent Operating Margin value of 33.05%, 4AB belongs to the best of the industry, outperforming 89.16% of the companies in the same industry.
  • 4AB's Operating Margin has declined in the last couple of years.
  • Looking at the Gross Margin, with a value of 71.16%, 4AB is in the better half of the industry, outperforming 62.65% of the companies in the same industry.
  • 4AB's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 33.05%
PM (TTM) 3.94%
GM 71.16%
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
4AB.DE Yearly Profit, Operating, Gross Margins4AB.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

3

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so 4AB is creating value.
  • The number of shares outstanding for 4AB remains at a similar level compared to 1 year ago.
  • The number of shares outstanding for 4AB has been increased compared to 5 years ago.
  • Compared to 1 year ago, 4AB has a worse debt to assets ratio.
4AB.DE Yearly Shares Outstanding4AB.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B
4AB.DE Yearly Total Debt VS Total Assets4AB.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50B 100B 150B

2.2 Solvency

  • 4AB has an Altman-Z score of 2.38. This is not the best score and indicates that 4AB is in the grey zone with still only limited risk for bankruptcy at the moment.
  • 4AB has a Altman-Z score of 2.38. This is in the better half of the industry: 4AB outperforms 68.67% of its industry peers.
  • The Debt to FCF ratio of 4AB is 3.49, which is a good value as it means it would take 4AB, 3.49 years of fcf income to pay off all of its debts.
  • 4AB has a Debt to FCF ratio of 3.49. This is amongst the best in the industry. 4AB outperforms 81.93% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 3.49
Altman-Z 2.38
ROIC/WACC1.89
WACC8.29%
4AB.DE Yearly LT Debt VS Equity VS FCF4AB.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20B 40B 60B

2.3 Liquidity

  • A Current Ratio of 0.72 indicates that 4AB may have some problems paying its short term obligations.
  • 4AB has a worse Current ratio (0.72) than 75.90% of its industry peers.
  • 4AB has a Quick Ratio of 0.72. This is a bad value and indicates that 4AB is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Quick ratio value of 0.60, 4AB is not doing good in the industry: 75.90% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.72
Quick Ratio 0.6
4AB.DE Yearly Current Assets VS Current Liabilites4AB.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B

4

3. Growth

3.1 Past

  • 4AB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -12.09%.
  • Measured over the past 5 years, 4AB shows a small growth in Earnings Per Share. The EPS has been growing by 2.51% on average per year.
  • 4AB shows a small growth in Revenue. In the last year, the Revenue has grown by 7.40%.
  • Measured over the past years, 4AB shows a quite strong growth in Revenue. The Revenue has been growing by 11.11% on average per year.
EPS 1Y (TTM)-12.09%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%-38%
Revenue 1Y (TTM)7.4%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%9.1%

3.2 Future

  • 4AB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.67% yearly.
  • 4AB is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.50% yearly.
EPS Next Y7.3%
EPS Next 2Y19.85%
EPS Next 3Y16.87%
EPS Next 5Y13.67%
Revenue Next Year8.74%
Revenue Next 2Y9.13%
Revenue Next 3Y8.7%
Revenue Next 5Y7.5%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4AB.DE Yearly Revenue VS Estimates4AB.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20B 40B 60B 80B
4AB.DE Yearly EPS VS Estimates4AB.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15 20

6

4. Valuation

4.1 Price/Earnings Ratio

  • 4AB is valuated rather expensively with a Price/Earnings ratio of 23.03.
  • 81.93% of the companies in the same industry are more expensive than 4AB, based on the Price/Earnings ratio.
  • 4AB's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.54.
  • A Price/Forward Earnings ratio of 14.97 indicates a correct valuation of 4AB.
  • 91.57% of the companies in the same industry are more expensive than 4AB, based on the Price/Forward Earnings ratio.
  • When comparing the Price/Forward Earnings ratio of 4AB to the average of the S&P500 Index (24.31), we can say 4AB is valued slightly cheaper.
Industry RankSector Rank
PE 23.03
Fwd PE 14.97
4AB.DE Price Earnings VS Forward Price Earnings4AB.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • 79.52% of the companies in the same industry are more expensive than 4AB, based on the Enterprise Value to EBITDA ratio.
  • 4AB's Price/Free Cash Flow ratio is rather cheap when compared to the industry. 4AB is cheaper than 87.95% of the companies in the same industry.
Industry RankSector Rank
P/FCF 19.54
EV/EBITDA 15.88
4AB.DE Per share data4AB.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 -40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates 4AB does not grow enough to justify the current Price/Earnings ratio.
  • 4AB has a very decent profitability rating, which may justify a higher PE ratio.
  • 4AB's earnings are expected to grow with 16.87% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.15
PEG (5Y)9.17
EPS Next 2Y19.85%
EPS Next 3Y16.87%

6

5. Dividend

5.1 Amount

  • 4AB has a Yearly Dividend Yield of 3.09%. Purely for dividend investing, there may be better candidates out there.
  • Compared to an average industry Dividend Yield of 0.76, 4AB pays a better dividend. On top of this 4AB pays more dividend than 96.39% of the companies listed in the same industry.
  • 4AB's Dividend Yield is rather good when compared to the S&P500 average which is at 1.92.
Industry RankSector Rank
Dividend Yield 3.09%

5.2 History

  • On average, the dividend of 4AB grows each year by 7.72%, which is quite nice.
Dividend Growth(5Y)7.72%
Div Incr Years4
Div Non Decr Years4
4AB.DE Yearly Dividends per share4AB.DE Yearly Dividends per shareYearly Dividends per share 2020 2021 2022 2023 2024 2025 2026 2 4 6

5.3 Sustainability

  • 489.69% of the earnings are spent on dividend by 4AB. This is not a sustainable payout ratio.
  • 4AB's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP489.69%
EPS Next 2Y19.85%
EPS Next 3Y16.87%
4AB.DE Yearly Income VS Free CF VS Dividend4AB.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B
4AB.DE Dividend Payout.4AB.DE Dividend Payout, showing the Payout Ratio.4AB.DE Dividend Payout.PayoutRetained Earnings

ABBVIE INC

FRA:4AB (1/16/2026, 5:28:00 PM)

187.2

-0.2 (-0.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-31
Earnings (Next)02-04
Inst Owners75.04%
Inst Owner ChangeN/A
Ins Owners0.05%
Ins Owner ChangeN/A
Market Cap330.85B
Revenue(TTM)59.64B
Net Income(TTM)2.35B
Analysts78.38
Price Target212.95 (13.76%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 3.09%
Yearly Dividend5.36
Dividend Growth(5Y)7.72%
DP489.69%
Div Incr Years4
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.85%
Min EPS beat(2)0.95%
Max EPS beat(2)2.75%
EPS beat(4)4
Avg EPS beat(4)1.21%
Min EPS beat(4)0.02%
Max EPS beat(4)2.75%
EPS beat(8)7
Avg EPS beat(8)0.95%
EPS beat(12)9
Avg EPS beat(12)0.65%
EPS beat(16)11
Avg EPS beat(16)0.49%
Revenue beat(2)1
Avg Revenue beat(2)-0.08%
Min Revenue beat(2)-0.79%
Max Revenue beat(2)0.63%
Revenue beat(4)2
Avg Revenue beat(4)0.22%
Min Revenue beat(4)-0.79%
Max Revenue beat(4)1.23%
Revenue beat(8)4
Avg Revenue beat(8)0.31%
Revenue beat(12)5
Avg Revenue beat(12)-0.17%
Revenue beat(16)5
Avg Revenue beat(16)-0.74%
PT rev (1m)-0.14%
PT rev (3m)8.34%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.79%
EPS NY rev (1m)0.02%
EPS NY rev (3m)-11.46%
Revenue NQ rev (1m)-0.04%
Revenue NQ rev (3m)0.47%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)0.49%
Valuation
Industry RankSector Rank
PE 23.03
Fwd PE 14.97
P/S 6.45
P/FCF 19.54
P/OCF 18.44
P/B N/A
P/tB N/A
EV/EBITDA 15.88
EPS(TTM)8.13
EY4.34%
EPS(NY)12.5
Fwd EY6.68%
FCF(TTM)9.58
FCFY5.12%
OCF(TTM)10.15
OCFY5.42%
SpS29.03
BVpS-1.29
TBVpS-45.07
PEG (NY)3.15
PEG (5Y)9.17
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 1.75%
ROE N/A
ROCE 20.86%
ROIC 15.64%
ROICexc 16.59%
ROICexgc 572.43%
OM 33.05%
PM (TTM) 3.94%
GM 71.16%
FCFM 33%
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
ROICexc(3y)15.06%
ROICexc(5y)13.91%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)17.54%
ROCE(5y)16.27%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-1.81%
ROICexc growth 5Y-14.87%
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
F-Score7
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 3.49
Debt/EBITDA 2.39
Cap/Depr 14.25%
Cap/Sales 1.97%
Interest Coverage 250
Cash Conversion 74.59%
Profit Quality 838.33%
Current Ratio 0.72
Quick Ratio 0.6
Altman-Z 2.38
F-Score7
WACC8.29%
ROIC/WACC1.89
Cap/Depr(3y)9.59%
Cap/Depr(5y)10.06%
Cap/Sales(3y)1.45%
Cap/Sales(5y)1.5%
Profit Quality(3y)361.43%
Profit Quality(5y)328.91%
High Growth Momentum
Growth
EPS 1Y (TTM)-12.09%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%-38%
EPS Next Y7.3%
EPS Next 2Y19.85%
EPS Next 3Y16.87%
EPS Next 5Y13.67%
Revenue 1Y (TTM)7.4%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%9.1%
Revenue Next Year8.74%
Revenue Next 2Y9.13%
Revenue Next 3Y8.7%
Revenue Next 5Y7.5%
EBIT growth 1Y27.38%
EBIT growth 3Y-5.38%
EBIT growth 5Y3.87%
EBIT Next Year9.3%
EBIT Next 3Y15.61%
EBIT Next 5Y10.95%
FCF growth 1Y-20.4%
FCF growth 3Y-6.75%
FCF growth 5Y6.9%
OCF growth 1Y-18.24%
OCF growth 3Y-6.19%
OCF growth 5Y7.14%

ABBVIE INC / 4AB.DE FAQ

What is the ChartMill fundamental rating of ABBVIE INC (4AB.DE) stock?

ChartMill assigns a fundamental rating of 5 / 10 to 4AB.DE.


What is the valuation status for 4AB stock?

ChartMill assigns a valuation rating of 6 / 10 to ABBVIE INC (4AB.DE). This can be considered as Fairly Valued.


How profitable is ABBVIE INC (4AB.DE) stock?

ABBVIE INC (4AB.DE) has a profitability rating of 6 / 10.


Can you provide the financial health for 4AB stock?

The financial health rating of ABBVIE INC (4AB.DE) is 3 / 10.


How sustainable is the dividend of ABBVIE INC (4AB.DE) stock?

The dividend rating of ABBVIE INC (4AB.DE) is 6 / 10 and the dividend payout ratio is 489.69%.